Generic Name: daclatasvir (dak LAT as vir)

Brand Name: Daklinza

What is daclatasvir?

Daclatasvir is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body.

Daclatasvir is used to treat genotype 3 chronic hepatitis C in adults without cirrhosis. This medicine is given together with another drug called sofosbuvir.

Daclatasvir may also be used for purposes not listed in this medication guide.

What is the most important information I should know about daclatasvir?

Serious drug interactions can occur when certain medicines are used together with daclatasvir. Tell each of your healthcare providers about all medicines you use now, and any medicine you start or stop using.

Daclatasvir (trade name Daklinza) is a drug for the treatment of hepatitis C (HCV). It was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daklinza gained its FDA approval on July 24, 2015 in the United States; it is approved for hepatitis C genotype 3 infections.

Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.

It is on the World Health Organization’s List of Essential Medicines, a list of the most important medications needed in a basic health system. There has been controversy over the price that Bristol-Myers Squibb has chosen to charge for the drug. As of December 2015 it costs between $50,000 and $84,000 in high-income countries. A generic version of daclatasvir was approved in India in December 2015 and is currently being sold under brand names NATDAC (produced by Natco Pharma) and MyDacla (produced byMylan).